| Youssef S Yammine, MD | |
|
3311 E Murdock St, Wichita, KS 67208-3054 | |
| (316) 689-9325 | |
| (316) 689-9363 |
| Full Name | Youssef S Yammine |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 20 Years |
| Location | 3311 E Murdock St, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295957587 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| Via Christi Hospital Wichita St Teresa, Inc | Wichita, KS | Hospital |
| Kansas Medical Center Llc | Andover, KS | Hospital |
| Wesley Medical Center | Wichita, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Medical Group Via Christi, Pa | 2961314497 | 177 |
| Ascension Via Christi Hospitals Wichita Inc | 5799696944 | 70 |
News Archive
Researchers have sequenced the genomes of two parasites that cause bilharzia or schistosomiasis - a disease transmitted by water-borne snails that affects more than 200 million people worldwide - "revealing potential weaknesses that could be exploited by drug developers," Nature reports (Smith, 7/15).
Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.
A new study finds that in regions where indigenous Australians most readily accepted a government incentive to lower drug copayments, hospitalizations to treat the population's chronic conditions declined by 40 percent in just two years.
Researchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portugal studied new protective properties of vitamin C in cells from the human skin, which could lead to better skin regeneration.
Using human skin cells, University of California, Irvine neurobiologists and their colleagues have created a method to generate one of the principle cell types of the brain called microglia, which play a key role in preserving the function of neural networks and responding to injury and disease.
› Verified 8 days ago
| Entity Name | Ascension Medical Group Via Christi, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063453991 PECOS PAC ID: 2961314497 Enrollment ID: O20031104000089 |
News Archive
Researchers have sequenced the genomes of two parasites that cause bilharzia or schistosomiasis - a disease transmitted by water-borne snails that affects more than 200 million people worldwide - "revealing potential weaknesses that could be exploited by drug developers," Nature reports (Smith, 7/15).
Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.
A new study finds that in regions where indigenous Australians most readily accepted a government incentive to lower drug copayments, hospitalizations to treat the population's chronic conditions declined by 40 percent in just two years.
Researchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portugal studied new protective properties of vitamin C in cells from the human skin, which could lead to better skin regeneration.
Using human skin cells, University of California, Irvine neurobiologists and their colleagues have created a method to generate one of the principle cell types of the brain called microglia, which play a key role in preserving the function of neural networks and responding to injury and disease.
› Verified 8 days ago
| Entity Name | Ascension Via Christi Hospitals Wichita Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871589333 PECOS PAC ID: 5799696944 Enrollment ID: O20031118000404 |
News Archive
Researchers have sequenced the genomes of two parasites that cause bilharzia or schistosomiasis - a disease transmitted by water-borne snails that affects more than 200 million people worldwide - "revealing potential weaknesses that could be exploited by drug developers," Nature reports (Smith, 7/15).
Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.
A new study finds that in regions where indigenous Australians most readily accepted a government incentive to lower drug copayments, hospitalizations to treat the population's chronic conditions declined by 40 percent in just two years.
Researchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portugal studied new protective properties of vitamin C in cells from the human skin, which could lead to better skin regeneration.
Using human skin cells, University of California, Irvine neurobiologists and their colleagues have created a method to generate one of the principle cell types of the brain called microglia, which play a key role in preserving the function of neural networks and responding to injury and disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Youssef S Yammine, MD Po Box 8035, Wichita, KS 67208-0035 Ph: (316) 689-9135 | Youssef S Yammine, MD 3311 E Murdock St, Wichita, KS 67208-3054 Ph: (316) 689-9325 |
News Archive
Researchers have sequenced the genomes of two parasites that cause bilharzia or schistosomiasis - a disease transmitted by water-borne snails that affects more than 200 million people worldwide - "revealing potential weaknesses that could be exploited by drug developers," Nature reports (Smith, 7/15).
Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.
A new study finds that in regions where indigenous Australians most readily accepted a government incentive to lower drug copayments, hospitalizations to treat the population's chronic conditions declined by 40 percent in just two years.
Researchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portugal studied new protective properties of vitamin C in cells from the human skin, which could lead to better skin regeneration.
Using human skin cells, University of California, Irvine neurobiologists and their colleagues have created a method to generate one of the principle cell types of the brain called microglia, which play a key role in preserving the function of neural networks and responding to injury and disease.
› Verified 8 days ago
Ahmad Qaddour, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9300 E 29th St N, Suite 310, Wichita, KS 67226 Phone: 316-858-9000 Fax: 316-858-9005 | |
Kathryn Watkins Brickman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 550 N Hillside St, Wichita, KS 67214 Phone: 316-962-2000 Fax: 303-306-7753 | |
Ray F Fisher, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 818 N Carriage Pkwy, Wichita, KS 67208 Phone: 316-651-2252 Fax: 316-651-2314 | |
Mitchell A Morgan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1131 S Clifton Ave, Suite B, Wichita, KS 67218 Phone: 316-462-1040 Fax: 316-462-1042 | |
Dr. Kent B Murray, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-651-3603 Fax: 316-651-6666 | |
Dr. Raghu C Chaparala, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2160 W 21st St N, Wichita, KS 67203 Phone: 316-267-7175 Fax: 316-425-7799 | |
Layne M Reusser, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9350 E 35th St N, Ste 101, Wichita, KS 67226 Phone: 316-265-1308 Fax: 316-712-9286 |